获大股东增持H股复星医药(02196.HK)反覆续涨逾9%破顶 A股反覆涨逾9%
获大股东增持的复星医药(02196.HK)今早略低开早段曾失守10天线(59.3元),回吐至57.4元获承接,掉头向上兼突破5月10日所创上市高位62.8元,午後高见65.7元,现造65.6元,续升9.3%,成交增至1,421万股;其A股反覆高见70.43元人民币,现造70.35元人民币,急涨9.4%。
复星医药昨天公布,去年12月至本月21日期间,控股股东复星高科技及其控股股东Fosun International累计增持公司2,593.05万股H股(涉资约8.69亿人民币),总持股量增至10.13亿股,占公司总股本39.55%。另外,复星医药近日完成发行2021年第二期15亿人民币超短期融资券,期限120天,利率2.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.